A Visual Guide to Scleroderma and Approach to Treatment
A Visual Guide to Scleroderma and Approach to Treatment offers a focused analysis of the diagnosis and management of scleroderma. Specifically designed to enlighten and update students and trainees, practicing rheumatologists and general practitioners on the various forms of systemic sclerosis, the book is designed to be an easily accessible tool that also covers potential complications and the latest treatment developments. A Visual Guide to Scleroderma and Approach to Treatment emphasizes recognition of common clinical features by focusing on and illustrating severe and less severe forms of the disease that can involve internal organs such as the gastrointestinal tract, heart, lungs and kidneys. Photos and radiographs introduce each chapter and are accompanied by a guide to workup and treatment. A comprehensive and invaluable addition to the literature, this text is not only a necessary resource for students, trainees and primary care physicians; it will also be of significant interest to specialists in the fields of rheumatology, dermatology, pulmonology, cardiology, gastroenterology and nephrology. Maureen D. Mayes is a rheumatologist and Professor of Medicine in the Division of Rheumatology and Clinical Immunogenetics at the University of Texas-Houston Medical School where she directs the Scleroderma Clinic. She is currently the Principal Investigator of the NIH/NIAMS funded 'Scleroderma Family Registry and DNA Repository' and is author of more than 80 publications relating to scleroderma, its complications and its treatment. Dr. Mayes obtained her Masters of Public Health at the University of Michigan where she studied the epidemiology of scleroderma, resulting in a comprehensive analysis of the prevalence, incidence and survival of this disease. As Principal Investigator of the Scleroderma Family Registry and DNA Repository, she is currently studying the role of genetic factors in scleroderma susceptibility and disease severity. Dr. Mayes also conducts clinical treatment trials in scleroderma, both NIH and industry sponsored.
Weiterlesen weniger lesen